Herbert Smith Freehills is delighted to announce it is strengthening its longstanding relationship with Médecins Sans Frontières, one of the world's leading humanitarian charities, through a new five-year partnership worth up to £2 million.
Over the next five years Herbert Smith Freehills will support up to the value of £2m by:
- increase its direct donations and setting a global fundraising target worth up to £200,000 annually;
- increase its pro bono support to provide services worth up to £200,000 annually;
- and encourage more volunteers across the firm to use their skills to support MSF's work.
Financial assistance allows Médecins Sans Frontières to react to emergencies as soon as they occur and give high-quality care to those who need it most. Through pro bono and volunteer support, Herbert Smith Freehills helps MSF in a wide variety of ways – from providing legal training and hosting 'Mapathons' to chart areas where humanitarian organisations are trying to meet the needs of vulnerable people.
Discussing the enhanced partnership, Herbert Smith Freehills CEO Mark Rigotti said:
"MSF's assistance allows some of the world's most vulnerable people to survive – and thrive – when they need help most. I am extremely proud of our partnership with MSF, and I am delighted that we are renewing our commitment and reinforcing our relationship all across the firm."
Herbert Smith Freehills' work with Médecins Sans Frontières started seven years ago, in Australia, and has since grown to include relationships with offices in London, Johannesburg, Paris, Belfast, Hong Kong and Singapore. The firm has supported MSF's life-saving work through a wide range of activities including: helping MSF source a new supplier of HR and payroll systems that is both more efficient and cost effective, saving money on administrative costs; London's IT Training team delivered Excel training to MSF staff; the Sydney Employment team assisted with a number of matters, including advising on racial discrimination and diversity requirements in Australia; and Johannesburg advised on a laboratory-services agreement and clinical drugs trials for a project seeking to develop a more effective treatment for people with drug-resistant tuberculosis.